Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer

Item

http://www.wikidata.org/entity/Q33400687

Q33400687

about

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy DNA repair targeted therapy: The past or future of cancer treatment?Targeting the Checkpoint to Kill Cancer Cells Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.Development of synthetic lethality anticancer therapeutics.Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.A novelly synthesized phenanthroline derivative is a promising DNA-damaging anticancer agent inhibiting G1/S checkpoint transition and inducing cell apoptosis in cancer cells.Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design.PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.Cell cycle inhibitors for the treatment of NSCLC.Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma.Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.ATR/CHK1 inhibitors and cancer therapy.Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.

P2860

Q26745686-0E0A5CFC-A360-4A21-8906-67B7E39E60C4 Q26768679-B5D0849E-7CD2-4B65-BFEE-2A3C743E80F6 Q26795781-C31312B0-28C2-4D1C-84DA-9724A4041607 Q26863501-2D0BA73E-2BEE-433B-BB38-4A864CF40FF1 Q26864870-BF7E5CCC-D2B4-44CF-8E69-B0C6AC96050E Q28533896-6303B8A2-F696-43C7-A988-6C017335A83E Q33439342-8C2A7678-4452-4311-A6E6-0A651DD408FD Q34380368-76EF4A92-ACDC-440C-87C7-2182C88A0F0D Q35073758-B0F5954D-414E-4676-B8E2-D61200D8FBC6 Q35201518-59F7690F-DD8A-413F-BC38-55C7D0B1B037 Q35847932-17984756-F0C3-4B14-93E5-AF58D012C08D Q36546469-A411C29B-0696-4C54-8923-62AC81BB0EC7 Q36901517-5CD89DB9-63EE-4BBD-AFDB-9718A1B36CC8 Q37376388-4112EF21-DB91-42BB-916A-E938BB904A29 Q37718444-53160C8D-8E1D-465E-8697-818E287F0AEC Q38199197-72D51F16-7E1E-4D38-B4F6-AB6BFE13CA47 Q38695896-5D2EB40C-CBEC-4466-86FA-3794445D9407 Q38901610-6E65AD3F-9539-41D2-9096-E50074667A0D Q38983310-D8CBE80B-C641-4222-A0B2-05F5D631D64A Q38984960-F76855BB-4EF1-46C0-B69E-24736BC1C3D8 Q39650689-978917C7-1178-48B1-904B-9AF4802BE024 Q41761375-2C4F0DB7-FED2-4863-85EF-CF8109D3FBE8 Q47622968-8DB98067-14CC-4B90-95F0-BB8458682272 Q54316808-FF4C3C00-6EB5-480D-A789-9F95E73A24F1 Q55035826-8F0FBCA6-70B0-4A75-924F-BB38125496A6

P2860

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer

Item

http://www.wikidata.org/entity/Q33400687

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu